A comparison of the efficacy of topical adapalene gel 0.1% with tretinoin gel 0.025% in mild acne vulgaris
DOI:
https://doi.org/10.66344/jpad.27.1.2017.1024Keywords:
Acne, adapalene, tretinoinAbstract
Objective  To compare the efficacy of topical adapalene with topical tretinoin in the treatment of mild acne vulgaris . Methods  This randomized controlled trial was conducted over a period of 6 months in outpatient department of dermatology, Lady Reading Hospital, Peshawar. 101 patients were taken after nonprobability consecutive sampling in each group. Topical adapalene 0.1% gel was given to group A while topical tretinoin 0.025% gel was given to group B for once daily application. Efficacy was ascertained after the end of third month and was graded as excellent or poor response. The data were statistically analyzed using SPSS version 11. Results  Out of 202 patients, male and female patients were 91 and 111, respectively with male to female ratio 0.8:1. The age of the patients ranged from 15-25 years. Mean age in group A was 19.79 ± 2.24  years while in group B, it was 20.11 ± 2.53  years. Overall efficacy in adapalene group was 84.2% as compared to 39.6% of tretinoin group (p=0.000). Conclusion  Topical adapalene has a better efficacy than topical tretinoin in the treatment of mild acne vulgaris .ÂReferences
Ahmad I, Sarwar M. Topical adapalene cream 0.1% versus isotretinoin 0.05% in the treatment of acne vulgaris: a randomized open label clinical trial. J Pak Assoc Dermatol. 2009;19:23-6.
James WD. Acne. N Eng J Med. 2005;352:1463-72.
Orringer JS, Kang S, Hamilyon T, Schumacher W, Cho S, Hammeberg C et al. Treatment of acne vulgaris with a pulsed dye laser: a randomized control trial. JAMA. 2004;291:2834-9.
Kapadia NF, Khalid G, Burhany T, Nahoda T. Comparative efficacy and safety and efficacy of systemic 13-cis retinoic acid 20mg/day vs 40mg/day in acne vulgaris. J Pak Assoc Dermatol. 2005;15:238-41.
James WD. Clinical practice acne. N Eng J Med. 2005;352:1463-72.
Tan HH, Tan WW, Barkham T, Yan XY, Zhu M. Community based study of acne vulgaris in adolescents in Singapore. Br J Dermatol. 2007;157:547-51.
Collier CN, Harper JC, Cafardi JA. The prevalence of acne in adults 20years and older. J Am Acad Dermatol. 2008;58:56-9.
Derno B, Poli F. Epidemiology of acne. Dermatology. 2003;206:7-10.
Amin K, Riddle CC, Aries DJ, Schweiger ES. Common and alternate oral antibiotic therapies for acne vulgaris. J Drugs Dermatol. 2007;6:873-80.
Irby CE, Yentzer BA, Feldman SR. A review of adapalene in the treatment of acne vulgaris. J Adolescent Health. 2008;43:421-4.
Iftikhar U, Aman S, Nadeem M, Kazmi AH. A comparison of efficacy and safety of topical 0.1% adapalene and 4% benzoyl peroxide in the treatment of mild to moderate acne vulgaris. J Pak Assoc Dermatol. 2009;19:141-5.
Campbell JL, Weiss JS. The results of the MORE trial: overview. Cutis. 2006;78:5-11.
Grosshans M, Marks R, Mascaro JM, Torras H, Meynadier J, Alirezai M et al. Evaluation of clinical efficacy and safety of adapalene 0·1% gel versus tretinoin 0·025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol. 1998;139:26-33.
Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol. 2007;21:747-53.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
